Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEN 1611

Next Previous
Drug Profile

MEN 1611

Alternative Names: CH-5132799; MEN-1611; PA-799

Latest Information Update: 27 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharma Europe
  • Developer Berlin Chemie; Chugai Pharma Europe; Menarini Ricerche
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; HER2 negative breast cancer
  • No development reported HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 27 Feb 2024 Menarini Ricerche completes a phase-I/II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Germany (PO) (NCT04495621)
  • 23 Feb 2024 Menarini Group completes phase I B-PRECISE-01 trial in Her2 positive Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA, United Kingdom, France, Belgium, Spain and Italy (PO) (NCT03767335)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top